Short Interest in Zura Bio Limited (NASDAQ:ZURA) Increases By 183.4%

Zura Bio Limited (NASDAQ:ZURA) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 4,960,000 shares, a growth of 183.4% from the October 31st total of 1,750,000 shares. Currently, 10.6% of the company’s shares are sold short. Based on an average daily trading volume, of 444,500 shares, the days-to-cover ratio is presently 11.2 days.

Insiders Place Their Bets

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. This represents a 2.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The disclosure for this sale can be found here. 22.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Zura Bio

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after acquiring an additional 6,412 shares during the last quarter. Forefront Analytics LLC increased its holdings in shares of Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Zura Bio in the 3rd quarter valued at approximately $46,000. Finally, AQR Capital Management LLC acquired a new stake in Zura Bio in the 2nd quarter worth approximately $43,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Price Performance

Shares of NASDAQ:ZURA opened at $3.00 on Thursday. The firm has a 50 day moving average of $4.12 and a 200 day moving average of $4.03. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Piper Sandler restated an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Chardan Capital dropped their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Finally, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.80.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.